Mesoblast to Host R&D Day on April 8, 2026
Rhea-AI Summary
Mesoblast (Nasdaq: MESO) will hold its inaugural R&D Day on April 8, 2026 in New York City, with a live webcast from 8:00am–11:00am EST.
The program will feature senior leadership and key opinion leaders, discuss corporate strategy, commercialization of Ryoncil, the company’s multi‑billion‑dollar pipeline in inflammatory pain and cardiovascular disease, and unveil new cellular medicine technology. A replay will be posted on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – MESO
On the day this news was published, MESO gained 0.69%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While MESO slipped 0.68%, key biotech peers like DYN, SRPT, and AUPH showed gains between 0.75% and 3.32%, suggesting today’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Leadership appointment | Positive | -3.6% | New Head of Clinical Development and Medical Affairs to advance programs. |
| Feb 26 | H1 FY2026 results | Positive | -6.3% | H1 FY2026 revenue growth, improved net loss, and Ryoncil guidance. |
| Feb 20 | Earnings webcast | Neutral | -0.2% | Announcement of webcast for operational highlights and financial results. |
| Feb 11 | Clinical data update | Positive | -7.7% | High survival EIND data and plans for pivotal adult SR-aGvHD trial. |
| Jan 28 | Ryoncil sales update | Positive | -4.0% | Ryoncil quarterly sales growth and non-dilutive credit facility details. |
Recent MESO news and updates, including earnings, clinical data, and revenue growth, have often been followed by negative next-day price moves, indicating a pattern of selling into news.
Over the last few months, Mesoblast has reported growing Ryoncil® revenues, secured a US$125M credit facility, and highlighted strong EIND survival data and upcoming pivotal trials. An interim H1 FY2026 update showed improving losses and detailed its commercialization ramp. Management also strengthened clinical leadership with a new Head of Clinical Development and Medical Affairs. Despite generally constructive operational updates, the stock saw negative 24h moves after each of these prior announcements, providing context for how investors reacted to company communications.
Market Pulse Summary
This announcement schedules Mesoblast’s inaugural R&D Day on April 8, 2026, highlighting corporate strategy, Ryoncil® commercialization, pipeline opportunities, and new technology. In recent months, the company detailed growing Ryoncil® revenues, pivotal-trial plans, and added senior clinical leadership. Investors may focus on how this event expands on those disclosures, particularly around inflammatory pain and cardiovascular programs, commercialization progress, and clearly defined upcoming milestones that can validate the long-term growth narrative.
AI-generated analysis. Not financial advice.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders.
The event will include discussions regarding the company’s corporate strategy, successful commercialization of its flagship product Ryoncil®, and its robust multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. In addition, the company will unveil new technology that will drive innovation for the next era of cellular medicines.
Dr. Silviu Itescu, Chief Executive of Mesoblast, said: ”Our inaugural R&D event provides an opportunity to highlight Mesoblast's near-term and longer-term corporate drivers of growth, and upcoming key milestones of our deep pipeline.”
The webcast can be accessed via: https://webcast.openbriefing.com/msb-inv-2026/
A replay of the webcast will be available shortly after the conclusion of event on the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Rubenstein | BlueDot Media |
| Caroline Nelson | Steve Dabkowski |
| T: +1 703 489 3037 | T: +61 419 880 486 |
| E: cnelson@rubenstein.com | E: steve@bluedot.net.au |
FAQ
When is Mesoblast (MESO) hosting its inaugural R&D Day and how long will the event last?
How can investors watch the Mesoblast (MESO) R&D Day webcast on April 8, 2026?
What topics will Mesoblast (MESO) cover during the April 8, 2026 R&D Day?
Will Mesoblast (MESO) discuss Ryoncil commercialization progress at the April 8, 2026 event?
Does Mesoblast (MESO) plan to announce new technology or pipeline details at the April 8, 2026 R&D Day?
